India Rejects Bayer’s Plea To Dismiss Natco’s Compulsory License On Sorafenib
This article was originally published in PharmAsia News
Executive Summary
Bayer’s arguments were countered as the appellate body said withdrawal of Natco’s compulsory license may jeopardize public interest.